Anti-hCD20-hIgA1

InvivoGen Kontakt z doradcą
Human CD20 (Rituximab) antibody - Human IgA1
Anti-hCD20-hIgA1

Anti-hCD20-hIgA1 features the constant region of the human IgA1 isotype and the variable region of rituximab.

Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes.

Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity.

Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia.

Anti-hCD20-hIgA1 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with peptide M.

Podobne produkty

Anti-hIFN-α7-IgG

Anti-hIFN-α7-IgG

InvivoGen
Więcej
Anti-HER2

Anti-HER2

InvivoGen
Więcej
Anti-hPD-L1-mIgG1

Anti-hPD-L1-mIgG1

InvivoGen
Więcej